Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 7, 2006, Pages 939-962

  Silvestri, Romano ^a   Maga, Giovanni ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

Author keywords

AIDS; HAART; HIV 1; Non nucleoside inhibitors; Structure activity relationships

Indexed keywords

EID: 34247179717     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.7.939     Document Type: Review

References (49)

1. MAGA G, SPADARI S: Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Curr. Drug Metab. (2002) 3(1):73-95. • Up-to-date review on the clinical use of NRTIs and NNRTIs with informations about toxic effects and drug-drug interactions.
2. CAMPIANI G, RAMUNNO A, MAGA G et al.: Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm. Des (2002) 8(8):615-657. • A comprehensive review of all NNRTIs families from a medicinal chemistry point of view.
3. ARNOLD E, DAS K, DING J et al.: Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des. Discov. (1996) 13(3-4):29-47.
4. BALZARINI J: Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. (1999) 58(1):1-27. (Pubitemid 29247372)
5. DEEKS SG: International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl. 1):S25-S33.
6. DE CLERCQ E: New anti-HIV agents and targets. Med. Res. Rev. (2002) 22(6):531-565.
7. CLOTET B: Efavirenz: resistance and cross-resistance. Int. J. Clin. Pract. Suppl. (1999) 103:21-25.
8. CORBETT JW, KO SS, RODGERS JD et al.: Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. (2000) 43(10):2019-2030.
9. TURNER BG, SUMMERS MF: Structural biology of HIV. J. Mol. Biol. (1999) 285(1):1-32. •• Excellent review on the structural aspects of HIV-1 proteins.
10. REN J, ESNOUF R, GARMAN E et al.: High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. (1995) 2:293-302. •• Seminal paper with the first high-resolution structures of HIV-1 RT complexed with different classes of NNRTIs.
11. TEMIZ NA, BAHAR I: Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins (2002) 49(1):61-70.
12. SPENCE RA, KATI WM, ANDERSON KS, JOHNSON KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 267:988-993. •• First pre steady-state kinetic analysis of the interaction between HIV-1 RT and NNRTIs.
13. SPENCE R, ANDERSON KS, JOHNSON KA: HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry (1996) 35:1054-1063. (Pubitemid 26034593)
14. TANTILLO C, DING J, JACOBO-MOLINA A et al.: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. (1994) 243(3):369-387. (Pubitemid 2146614)
15. ERICKSON JW, BURT SK: Structural mechanisms of HIV drug resistance. Ann. Rev. Pharmacol. Toxicol. (1996) 36:545-571. (Pubitemid 26169902)
16. MAGA G, AMACKER M, RUEL N, HUBSCHER U, SPADARI S: Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. (1997) 274(5):738-747.
17. REN J, MILTON J, WEAVER KL et al.: Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold. Des. (2000) 8(10):1089-1094. • Important contribution to the understanding of the mechanism of NNRTIs resistance caused by the K103N mutation.
18. LINDBERG J, SIGURDSSON S, LOWGREN S et al.: Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. (2002) 269(6):1670-1677.
19. PEDERSEN OS, PEDERSEN EB: Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antivir. Chem. Chemother. (1999) 10(6):285-314.
20. YOAKIM C, BONNEAU PR, DEZIEL R et al.: Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8- heteroarylthiomethyldipyrido-diazepinone derivatives. Bioorg. Med. Chem. Lett. (2004) 14(3):739-742.
21. BONNEAU PR, CYWIN CL, DEZIEL R et al.: Towards a second generation non-nucleoside reverse transcriptase inhibitors of HIV-1 with broad spectrum of activity. National Meeting of the American Chemical Society. New York, USA (2003).
22. BONNEAU PR, DOYON L, DUAN J et al.: Second generation non-nucleoside reverse transcriptase inhibitors of HIV-1. 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, USA (2004) Poster 530.
23. O'MEARA JA, YOAKIM C, BONNEAU PR et al.: Novel 8-substituted dipyridodiazepinone inhibitors with a broad spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. (2005) 48(17):5580-5588. (Pubitemid 41209255)
24. PAUWELS R, ANDRIES K, DEBYSER Z et al.: Potent and highly selective human immunodeficiency virus Type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA (1993) 90(5):1711-1715. (Pubitemid 23069926)
25. GRUZDEV B, HORBAN A, BORON-KACZMARSKA A et al.: TMC120, a new non-nucleoside reverse transcriptase inhibitor, is a potent antiretroviral in treatment naive, HIV-1 infected subjects. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2001).
26. SANKATSING S, WEVERLING G, VAN 'T KLOOSTER G, PRINS J, LANGE J: TMC125 monotherapy for 1 week results in a similar initial rate of decline of HIV-1 RNA as therapy with a 5-drug regimen. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA (2002).
27. JANSSEN PA, LEWI PJ, ARNOLD E et al.: In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amin o]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. (2005) 48(6):1901-1909.
28. GUILLEMONT J, PASQUIER E, PALANDJIAN P et al.: Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus Type 1. J. Med. Chem. (2005) 48(6):2072-2079. (Pubitemid 40396334)
29. HEERES J, DE JONGE MR, KOYMANS LM et al.: Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. J. Med. Chem. (2005) 48(6):1910-1918.
30. DE JONGE MR, KOYMANS LM, VINKERS HM et al.: Structure based activity prediction of HIV-1 reverse transcriptase inhibitors. J. Med. Chem. (2005) 48(6):2176-2183. (Pubitemid 40396345)
31. CHAN JH, FREEMAN GA, TIDWELL JH et al.: Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. (2004) 47(5):1175-1182. (Pubitemid 38229119)
32. HOPKINS AL, REN J, MILTON J et al.: Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J. Med. Chem. (2004) 47(24):5912-5922. (Pubitemid 39517015)
33. FREEMAN GA, ANDREWS III CW 3RD, HOPKINS AL et al.: Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. J. Med. Chem. (2004) 47(24):5923-5936.
34. CHIMIRRI A, GRASSO S, MOLICA C et al.: Anti-HIV agents. IV. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4 -a]benzimidazoles. Farmaco (1996) 51(4):279-282. (Pubitemid 26244845)
35. BARRECA ML, RAO A, DE LUCA L et al.: Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem. (2005) 48(9):3433-3437.
36. ARTICO M, SILVESTRI R, STEFANCICH G et al.: Synthesis of pyrryl aryl sulfones targeted at the HIV-1 reverse transcriptase. Arch. Pharm. (1995) 328(3):223-229.
37. ARTICO M, SILVESTRI R, MASSA S et al.: 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the antihuman immunodeficiency virus Type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. (1996) 39(2):522-530. (Pubitemid 26041464)
38. SILVESTRI R, DE MARTINO G, LA REGINA G et al.: Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem. (2003) 46(12):2482-2493.
39. SILVESTRI R, ARTICO M, DE MARTINO G et al.: Simple, short peptide derivatives of l-737,126 active in vitro against HIV-1 WT and variants carrying NNRTI resistance mutations. J. Med. Chem. (2004) 47(15):3892-3896.
40. CHAN JH, HONG JS, HUNTER RN et al.: 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. (2001) 44(12):1866-1882. (Pubitemid 32884512)
41. SILVESTRI R, ARTICO M: Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug-resistant mutants. Curr. Pharm. Des. (2005) 11(29):3779-3806.
42. LOKSHA YM, EL-BARBARY AA, EL-BADAWI MA et al.: Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazol es as novel Capravirine analogues. Bioorg Med. Chem. (2005) 13(13):4209-4220. (Pubitemid 40779390)
43. RANISE A, SPALLAROSSA A, SCHENONE S et al.: Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives. J. Med. Chem. (2003) 46(5):768-781.
44. RANISE A, SPALLAROSSA A, CESARINI S et al.: Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives. J. Med. Chem. (2005) 48(11):3858-3873.
45. BENJAHAD A, CROISY M, MONNERET C et al.: 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)- ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. J. Med. Chem. (2005) 48(6):1948-1964.
46. CANCIO R, SILVESTRI R, RAGNO R, et al.: High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus Type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme. Antimicrob. Agents. Chemother. (2005) 49(11):4546-4554
47. SANKATSING SU, WEVERLING GJ, PEETERS M et al.: TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. Aids (2003) 17(18):2623-2627.
48. GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYAE et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. Aids (2003) 17(17):2487-2494.
49. http://www.ClinicalTrials.gov/ct/action/ GetStudy Provides information about clinical research with human volunteers.